-
About
- Health
-
Patient Care
I Want To...
-
Research
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
-
School of Medicine
I Want to...
Find a Research Lab
-
Steven Menez Lab
Dr. Menez and his laboratory are interested in clinical and translational acute kidney injury (AKI) research, specifically with a focus on the transition between AKI and chronic kidney disease (CKD). Dr. Menez has investigated novel approaches to evaluate AKI using biomarkers of kidney injury, inflammation, and repair in the multi-center TRIBE-AKI and ASSESS-AKI Studies. Dr. Menez collaborates nationwide through the NIDDK-sponsored Kidney Precision Medicine Project, with a goal to improve the global understanding of kidney disease subgroups and identify new pathways and targets for novel therapies.
Since the start of the COVID-19 pandemic, he has additionally investigated the impact of COVID19 on kidney health, including short-term outcomes including need for dialysis or in-hospital mortality, as well as longer-term outcomes post-hospital discharge. -
Suzanne Topalian Lab
Our lab currently focuses on three areas of immunotherapy research: gaining a deeper knowledge of the biological underpinnings of human autoimmune response; discovering biomarkers that will help us identify which patients and tumor types are most likely to respond to various immune therapies; and developing immune-based treatment combinations that could deliver a more powerful anti-tumor response than monotherapies.
-
The Bigos Lab
The Bigos Lab focuses on a Precision Medicine approach to the treatment of psychiatric illness. In addition, this lab employs functional neuroimaging and genetics as biomarkers in neuropsychiatric drug development. A recent study used functional MRI to test the neural effects of a drug with the potential to treat cognitive dysfunction in schizophrenia. Other studies aim to identify patient-specific variables including sex, race, and genetics that impact drug clearance and clinical response to better select and dose antipsychotics and antidepressants.
-
The Pathak Lab
The Pathak lab is within the Division of Cancer Imaging Research in the Department of Radiology and Radiological Science. We develop novel imaging methods, computational models and visualization tools to ‘make visible’ critical aspects of cancer, stroke and neurobiology. Our research broadly encompasses the following areas: Functional and Molecular Imaging; Clinical Biomarker Development; Image-based Systems Biology and Visualization and Computational Tools. We are dedicated to mentoring the next generation of imagers, biomedical engineers and visualizers. Additional information can be found at www.pathaklab.org or by emailing Dr. Pathak.
-
Translational Neurobiology Laboratory
The goals of the Translational neurobiology Laboratory are to understand the pathogenesis and cell death pathways in neurodegenerative disorders to reveal potential therapeutic targets for pharmaceutical intervention; to investigate endogenous survival pathways and try to induce these pathways to restore full function or replace lost neurons; and to identify biomarkers to mark disease function or replace lost neurons; and to identify biomarkers to mark disease progression and evaluate therapeutics. Our research projects focus on models of Huntington's disease and Parkinson's disease. We use a combination of cell biology and transgenic animal models of these diseases.
-
Zhu Lab
The Zhu lab is focused on characterizing the activities of large collection of proteins, building signaling networks for better understanding the mechanisms of biological processes, and identifying biomarkers in human diseases and cancers.
More specifically, our group is interested in analyzing protein posttranslational modifications, and identifying important components involved in transcription networks and host-pathogen interactions on the proteomics level, and biomarkers in human IBD diseases. -
Zsuzsanna McMahan Lab
The Zsuzsanna McMahan Lab conducts translational research that seeks to identify the novel antigens in scleroderma and to define the target tissue in this disease. We are conducting two active clinical research trials, including one that studies skin biopsy specimens as biomarkers of scleroderma and the response to mycophenolate mofetil (MMF or Cellcept). The other study is a gastrointestinal involvement registry that follows patients who are experiencing GERD, small bowel bacterial overgrowth, constipation, fecal incontinence and gastroparesis to see if there is improvement in symptoms after a change in treatment is implemented.
